Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accumulated Expenses (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Accumulated Expenses for 9 consecutive years, with $5.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 32.72% year-over-year to $5.8 million, compared with a TTM value of $5.8 million through Dec 2025, up 32.72%, and an annual FY2025 reading of $5.8 million, up 32.72% over the prior year.
  • Accumulated Expenses was $5.8 million for Q4 2025 at Puma Biotechnology, down from $37.1 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $41.3 million in Q2 2022 and bottomed at $1.0 million in Q4 2023.
  • Average Accumulated Expenses over 5 years is $10.0 million, with a median of $4.5 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 2104.32% in 2024, then tumbled 95.42% in 2025.
  • Year by year, Accumulated Expenses stood at $3.9 million in 2021, then plummeted by 68.21% to $1.2 million in 2022, then decreased by 15.33% to $1.0 million in 2023, then skyrocketed by 318.39% to $4.4 million in 2024, then surged by 32.72% to $5.8 million in 2025.
  • Business Quant data shows Accumulated Expenses for PBYI at $5.8 million in Q4 2025, $37.1 million in Q3 2025, and $3.4 million in Q2 2025.